Rani Therapeutics Holdings, Inc. (RANI) News

Rani Therapeutics Holdings, Inc. (RANI): $11.32

3.09 (+37.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RANI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter RANI News Items

RANI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RANI News Highlights

  • RANI's 30 day story count now stands at 3.
  • Over the past 28 days, the trend for RANI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about RANI are KOSS, HUDI and LRN.

Latest RANI News From Around the Web

Below are the latest news stories about Rani Therapeutics Holdings Inc that investors may wish to consider to help them evaluate RANI as an investment opportunity.

Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results

- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - - Company announces preliminary consolidated financial results for the fourth quarter and year ended December 31, 2021 - SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Na

Yahoo | February 23, 2022

MNTS, KOSS and HTOO among mid-day movers

Gainers: Weidai (WEI) +79%.Rani Therapeutics Holdings (RANI) +33%.Stride LRN +29%.Exela Technologies XELA +26%.Huadi International (HUDI) +21%.Koss (KOSS) +20%.Sierra (SRRA)

Seeking Alpha | January 26, 2022

5 Biotech Stocks That Are Bucking the Selloff

Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.

Yahoo | January 19, 2022

Rani Therapeutics Appoints Lisa Rometty to Board of Directors

SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Rometty to its Board of Directors. Ms. Rometty brings significant global commercial leadership experience across a spectrum of start-ups to mature businesses in medical device, technology and pharmaceuticals. “In our effort to pioneer the fiel

Yahoo | January 7, 2022

Reviewing Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX)

Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]

Dakota Financial News | December 24, 2021

These are the top 10 best performing newly public Bay Area stocks

The parade to Wall Street was the biggest in decades, if ever, in 2021. But the portion of newly public companies that actually posted positive returns was a small fraction. Among the Bay Area contingent, these did the best.

Yahoo | December 21, 2021

Analysts Set Rani Therapeutics Holdings Inc (NASDAQ:RANI) Target Price at $23.50

Shares of Rani Therapeutics Holdings Inc (NASDAQ:RANI) have been assigned an average recommendation of Buy from the six research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages []

Dakota Financial News | December 18, 2021

Rani Therapeutics (NASDAQ:RANI) Shares Gap Down to $16.94

Rani Therapeutics Holdings Inc (NASDAQ:RANI)s stock price gapped down before the market opened on Friday . The stock had previously closed at $16.94, but opened at $16.18. Rani Therapeutics shares last traded at $16.88, with a volume of 201 shares. Several equities research analysts have commented on the company. Stifel Nicolaus assumed coverage on Rani []

Dakota Financial News | December 17, 2021

FY2021 Earnings Estimate for Rani Therapeutics Holdings Inc Issued By Cantor Fitzgerald (NASDAQ:RANI)

Rani Therapeutics Holdings Inc (NASDAQ:RANI) – Equities researchers at Cantor Fitzgerald lowered their FY2021 EPS estimates for Rani Therapeutics in a research note issued to investors on Monday, December 6th. Cantor Fitzgerald analyst B. Folkes now forecasts that the company will earn ($1.19) per share for the year, down from their prior estimate of ($0.76). […]

Transcript Daily | December 8, 2021

Rani Therapeutics (NASDAQ:RANI) Shares Gap Down to $25.68

Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares gapped down prior to trading on Friday . The stock had previously closed at $25.68, but opened at $24.52. Rani Therapeutics shares last traded at $24.51, with a volume of 714 shares traded. A number of brokerages have recently commented on RANI. BTIG Research began coverage on Rani Therapeutics […]

Dakota Financial News | December 3, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4978 seconds.